SNAP-8 (Acetyl Octapeptide-3)

Overview

SNAP-8 is a synthetic octapeptide — eight amino acids, acetylated at the N-terminus and amidated at the C-terminus — with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2 (one-letter: Ac-EEMQRRAD-NH2). It is best known under its cosmetic-ingredient (INCI) name Acetyl Octapeptide-3, and is marketed as a "neuromodulating" or "Botox-like" peptide intended to soften expression lines when applied topically.

The compound's identity and sequence are well documented: PubChem (CID 71587832) carries the SNAP-8 trade-mark and INCI synonyms and the UNII 8K14HJF88S. By direct calculation from the agreed sequence — matching commercial specification sheets — the amidated octapeptide has the molecular formula C41H70N16O16S and a molecular weight of ~1075.2 g/mol. (Databases actually disagree on the exact formula — see the chemistry note below — but the sequence is consistent.) Beyond that identity, the picture is much weaker. SNAP-8 was designed as an extension of the concept behind the related peptide Argireline (acetyl hexapeptide-8), and the efficacy claims that circulate for it — for example ~63% reduction in periocular wrinkle severity/depth after ~28 days at 10%, and being "~30% more active than Argireline" — trace to the original manufacturer's (Lipotec/Lubrizol) marketing and product literature, not to independent, peer-reviewed randomized controlled trials.

The honest reading is that SNAP-8 is a cosmetic ingredient with a defined structure and a plausible-sounding mechanism, but limited and largely industry-sourced human evidence. It is not an approved drug, and the premise that a large, hydrophilic octapeptide penetrates intact skin to reach neuromuscular junctions in meaningful amounts is itself not well established.

Chemistry and structure

SNAP-8 is a linear octapeptide, acetylated at the N-terminus and amidated at the C-terminus.

The sequence Ac-EEMQRRAD-NH2 is consistent across sources; the molecular formula and weight above follow by direct calculation from that sequence and match commercial specification sheets. Note that chemical databases disagree on the exact formula for this name (see below).

Mechanism of action

The rationale for SNAP-8 is extrapolated from SNARE/SNAP-25 biology and from the analogous peptide Argireline. It has not been directly demonstrated for SNAP-8 in humans.

• Proposed N-terminal SNAP-25 mimicry. SNAP-8 is described as a fragment mimic of the N-terminal domain of SNAP-25, competitively interfering with assembly of the SNARE complex, thereby reducing catecholamine/acetylcholine (neurotransmitter) release and attenuating the muscle contraction that drives expression lines. [Hypothesis / In vitro] — this is the mechanistic rationale asserted in cosmetic- industry and vendor literature, extrapolated from SNARE biology and from Argireline (acetyl hexapeptide-8). Direct experimental confirmation specific to SNAP-8 at the human neuromuscular junction after topical use is not established.
• Assumed skin penetration. For any of the above to matter cosmetically, the intact octapeptide would have to penetrate the skin barrier and reach a site of pharmacological action. This transdermal delivery of a large (~1075 g/mol), hydrophilic, charged peptide is not demonstrated and is a recognised open question for this class of "neuromodulating" peptides. [Hypothesis]

Research and evidence

The evidence for SNAP-8 is limited and largely industry-sourced. Its chemical identity is solid; its clinical efficacy is not independently established.

Human evidence

There is no well-established, independent, peer-reviewed randomized controlled trial of SNAP-8 located during this research. All quantitative efficacy figures that circulate — ~63% wrinkle reduction at ~28 days, ~21% at 7 days, and "~30% more active than Argireline" — trace to manufacturer or vendor literature, not to independent replication. A peer-reviewed review that does exist (PMC12193160) covers the related peptide Acetyl Hexapeptide-8 (Argireline), not SNAP-8 specifically, and highlights that skin permeability of such peptides is itself an open question. In short: robust independent human data isolating SNAP-8's topical anti-wrinkle effect is sparse, and the claims should be read as manufacturer-sourced [Human, industry-sponsored] rather than established fact.

Status and regulation

• Not an approved drug. SNAP-8 is not approved by the FDA or EMA as a medicine.
• Cosmetic ingredient. It is listed under the INCI name Acetyl Octapeptide-3 and is used as a topical cosmetic raw material.
• Substance record ≠ approval. It appears in the FDA/GSRS system (UNII 8K14HJF88S) as a substance record — an identifier registration, not a drug approval.
• Research reagent. It is also sold to the research/reagent market; research-grade material carries no human-use authorisation, and any intended human (including topical therapeutic) use would place it outside its cosmetic-ingredient framing.
• WADA. No WADA prohibited-list classification was found in any source reviewed. No class code (S0/S2) is asserted here — none should be inferred from its unapproved status.

Safety

• No established systemic safety or toxicology data. There is no established pharmacokinetic, safety, or toxicology dataset for injected or systemic human use — SNAP-8 is framed as a topical cosmetic only. Its safety outside that context is not characterised.
• Cosmetic use. As a cosmetic ingredient it is used topically at low concentrations; a formal, independent safety evaluation specific to SNAP-8 was not found in sources for this article, so no safety conclusion is asserted here.
• Research-grade material. Material sold as a research reagent is not manufactured to pharmaceutical standards; identity, purity, and contaminant profile cannot be assumed to be controlled.

Legal status

SNAP-8 is handled as a cosmetic raw material (INCI Acetyl Octapeptide-3) and as a research reagent ("for research use only"). Neither framing is authorisation for human therapeutic use. A cosmetic-ingredient listing is not a medicine approval, and "no specific ban" would not be affirmative permission: a compound becomes an unauthorised medicine the moment it is intended for human use. WADA sport-prohibition is a separate axis from legality, and no WADA class was found for SNAP-8, so none is stated. This is not legal advice; verify the current status in your own jurisdiction (dated 2026-07-08).

How it compares

SNAP-8 belongs to the small family of topical "neuromodulating" cosmetic peptides, the best known of which is Argireline (acetyl hexapeptide-8) — the peptide SNAP-8 was designed to extend and, per manufacturer literature, outperform. The comparison below is descriptive, not an endorsement or ranking.

The honest summary: SNAP-8 shares the same core limitation as other topical "neuromodulating" peptides — a plausible SNARE-based rationale but limited independent human evidence — and, unlike some cosmetic peptides, even its basic anti-wrinkle figures rest on manufacturer literature rather than independent trials.

Common misconceptions

• "SNAP-8 is a topical Botox." No. Botulinum toxin is a potent, injected, regulated biologic. SNAP-8 is a cosmetic peptide whose SNARE-mimic mechanism is a hypothesis/in-vitro extrapolation and whose skin penetration to a site of action is unproven. The comparison is marketing shorthand, not equivalence.
• "It's clinically proven to cut wrinkles by ~63%." That figure comes from the manufacturer's own literature, not from an independent peer-reviewed trial. No robust independent RCT of SNAP-8 was located.
• "The CAS number is 868844-74-0." That CAS is vendor-sourced and unverified — PubChem's SNAP-8 record lists no CAS, and it also appears under "acetyl octapeptide-1" in one database. Treat the CAS as not established.
• "A cosmetic listing means it's an approved, tested drug." An INCI cosmetic listing and a GSRS substance record are identifier/labelling frameworks, not drug approval and not evidence of clinical efficacy.